Key result
Fondaparinux achieves effective anticoagulation in the first reported case of total LMWH resistance.
Why the study?
Fondaparinux shares a mechanism of action with LMWH and is not expected to be an effective alternative in cases of LMWH resistance.
Does fondaparinux provide effective anticoagulation in a patient unresponsive to nadroparin?
Case Report (n=1)
Does fondaparinux provide effective anticoagulation in a patient unresponsive to nadroparin?
Answers are grounded in this paper and cite their sources.
Fondaparinux may be an effective alternative anticoagulant in patients with LMWH resistance.
WHAT IS KNOWN AND OBJECTIVE: Fondaparinux exhibits a similar mechanism of action as LMWH. Since both of these drugs bind to antithrombin and increase its affinity to factor Xa, fondaparinux is not expected to be an effective alternative anticoagulant to LMWH in case of LMWH resistance. CASE SUMMARY: We report on a case of effective anticoagulation using fondaparinux following total unresponsiveness to high doses of nadroparin administered twice daily, as confirmed via repeated anti-Xa measurements. The antithrombin levels were within the normal range. WHAT IS NEW AND CONCLUSION: To the best of our knowledge, this is the first report of the effective use of fondaparinux in the case of unresponsiveness to LMWH.
No takes yet. Share an insight, caveat, or question.
Hartinger et al. (2020) conducted a case report in Unresponsiveness to nadroparin (LMWH resistance) (n=1). Fondaparinux vs. Nadroparin was evaluated on Effective anticoagulation confirmed via anti-Xa measurements. Fondaparinux provided effective anticoagulation in a patient with total unresponsiveness to high-dose nadroparin, representing the first reported case of its efficacy in LMWH resistance.
Synapse has enriched 10 related papers. Consider them for comparative context: